Vis enkel innførsel

dc.contributor.authorDuijzer, Daniël
dc.contributor.authorde Winter, Maria A.
dc.contributor.authorCarrier, Marc
dc.contributor.authorCohen, Alexander T.
dc.contributor.authorHansen, John Bjarne
dc.contributor.authorKaasjager, Karin A.H.
dc.contributor.authorKakkar, Ajay K.
dc.contributor.authorMiddeldorp, Saskia
dc.contributor.authorSørensen, Henrik T.
dc.contributor.authorVisseren, Frank L.J.
dc.contributor.authorWells, Philip S.
dc.contributor.authorDorresteijn, Jannick A.N.
dc.contributor.authorNijkeuter, Mathilde
dc.date.accessioned2024-11-13T13:28:51Z
dc.date.available2024-11-13T13:28:51Z
dc.date.issued2024-09-11
dc.description.abstractBackground - After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE recurrence and bleeding to guide this decision.<p> <p>Objectives - To evaluate the impact of predicted individual risks of recurrence and bleeding on clinicians’ decisions on anticoagulation duration and to assess usefulness of the VTE-PREDICT calculator.<p> <p>Methods - A randomized controlled trial and within-subject study was conducted among clinicians treating VTE patients. The clinicians were asked to complete an online survey containing 6 fictional case vignettes. Group A proposed anticoagulant duration for each case without additional information first and subsequently after seeing calculator-predicted risks (within-subject analysis). Group B was directly provided with calculator risks and proposed treatment duration for each case vignette (for comparison with group A results in a randomized controlled trial analysis). Then, group B received questions on usefulness and credibility of the calculator.<p> <p>Results - Forty-five clinicians were assigned to group A and 48 to B. Overall, group A did not propose different anticoagulation durations than group B. However, individual clinicians in group A changed proposed duration in 35% of the cases after seeing the calculator risks. The calculator was considered useful and credible by most clinicians.<p> <p>Conclusion - Overall, use of the VTE-PREDICT calculator did not affect proposed anticoagulation duration. However, individual clinicians frequently changed their proposed duration after using the calculator, especially for patients with high bleeding risk.en_US
dc.identifier.citationDuijzer, de Winter, Carrier, Cohen, Hansen, Kaasjager, Kakkar, Middeldorp, Sørensen, Visseren, Wells, Dorresteijn, Nijkeuter. Impact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trial. Research and Practice in Thrombosis and Haemostasis (RPTH). 2024;8(7)
dc.identifier.cristinIDFRIDAID 2313404
dc.identifier.doi10.1016/j.rpth.2024.102569
dc.identifier.issn2475-0379
dc.identifier.urihttps://hdl.handle.net/10037/35703
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalResearch and Practice in Thrombosis and Haemostasis (RPTH)
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleImpact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trialen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)